OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. OPKO Health, Inc. is one of them.

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations spanning diagnostics, pharmaceuticals, and innovative therapies. Its business is anchored by BioReference Laboratories and a growing pipeline focused on immuno-oncology, immune rejuvenation, and metabolic disorders such as obesity.

In 2025, the company drew attention with notable insider buying. CEO Phillip Frost, OPKO’s largest shareholder with roughly 31% ownership, joined other key investors in boosting stakes, bringing the top five holders’ combined ownership to 51%. Recent share purchases around $1.32 suggest strong insider confidence in the company’s long-term outlook.

On the clinical front, OPK advanced a Phase 1 Epstein-Barr virus (EBV) vaccine in partnership with Merck, testing safety in up to 200 healthy adults. Results could lead to Phase 2 trials as early as next year. Its ModeX division continues to drive innovation in immuno-oncology, with four candidates in the pipeline, including MDX2001, a tetraspecific antibody for solid tumors now in Phase 1 trials. Other programs target lymphoma, leukemia, and immune dysfunction. OPK is also among stocks with insider buying, reflecting confidence from key shareholders in its pipeline and strategic direction.

Beyond oncology, OPKO Health, Inc. (NASDAQ:OPK) is addressing metabolic disorders through a collaboration with Entera Bio on OPK-88006, an oral dual GLP-1/glucagon agonist for obesity. Data presented at ENDO 2025 showed encouraging pharmacologic and pharmacokinetic results, with both oral and injectable formulations in development to meet the growing demand for obesity treatments.

OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1

Financially, OPK reported Q2 2025 revenue of $156.8 million, reflecting a decline from the prior year. However, the business recently sold select oncology testing assets from BioReference to Labcorp, a move designed to streamline operations and improve liquidity. With projected 2025 revenues of $640–$660 million, OPK is leaning on its pipeline, cost savings, and strategic divestitures to strengthen margins and move toward profitability.

While we acknowledge the risk and potential of OPK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OPK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.